Abstract
The incidence of esophageal squamous cell carcinoma (ESCC) is very high among the Turkmen population of Iran. Family studies suggest a genetic component to the disease. Turkmen are ethnically homogenous and are well suited for genetic studies. A previous study from China suggested that BRCA2 might play a role in the etiology of ESCC. We screened for mutations in the coding region of the BRCA2 gene in the germline DNA of 197 Turkmen patients with ESCC. A nonsense variant, K3326X, was identified in 9 of 197 cases (4.6%) vs 2 of 254 controls (0.8%) (OR=6.0, 95% CI=1.3–28; P=0.01). This mutation leads to the loss of the C-terminal domain of the BRCA2 protein, a part of the region of interaction with the FANCD2 protein. We observed nine other BRCA2 variants in single cases only, including two deletions, and seven missense mutations. Six of these were judged to be pathogenic. In total, a suspicious deleterious BRCA2 variant was identified in 15 of 197 ESCC cases (7.6%).
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 50 print issues and online access
$259.00 per year
only $5.18 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Akbari MR, Malekzadeh R, Nasrollahzadeh D, Amanian D, Sun P, Islami F et al. (2006). Familial risks of esophageal cancer among the Turkmen population of the Caspian littoral of Iran. Int J Cancer 119: 1047–1051.
Alter BP, Joenje H, Oostra AB, Pals G . (2005). Fanconi anemia: adult head and neck cancer and hematopoietic mosaicism. Arch Otolaryngol Head Neck Surg 131: 635–639.
Atanassov BS, Barrett JC, Davis BJ . (2005). Homozygous germ line mutation in exon 27 of murine Brca2 disrupts the Fancd2-Brca2 pathway in the homologous recombination-mediated DNA interstrand cross-links' repair but does not affect meiosis. Genes Chromosomes Cancer 44: 429–437.
Bork P, Blomberg N, Nilges M . (1996). Internal repeats in the BRCA2 protein sequence. Nat Genet 13: 22–23.
Daniels MJ, Wang Y, Lee M, Venkitaraman AR . (2004). Abnormal cytokinesis in cells deficient in the breast cancer susceptibility protein BRCA2. Science 306: 876–879.
Donoho G, Brenneman MA, Cui TX, Donoviel D, Vogel H, Goodwin EH et al. (2003). Deletion of Brca2 exon 27 causes hypersensitivity to DNA crosslinks, chromosomal instability, and reduced life span in mice. Genes Chromosomes Cancer 36: 317–331.
Fuks F, Milner J, Kouzarides T . (1998). BRCA2 associates with acetyltransferase activity when bound to P/CAF. Oncogene 17: 2531–2534.
Ghadirian P . (1985). Familial history of esophageal cancer. Cancer 56: 2112–2116.
Houghtaling S, Newell A, Akkari Y, Taniguchi T, Olson S, Grompe M . (2005). Fancd2 functions in a double strand break repair pathway that is distinct from non-homologous end joining. Hum Mol Genet 14: 3027–3033.
Houghtaling S, Timmers C, Noll M, Finegold MJ, Jones SN, Meyn MS et al. (2003). Epithelial cancer in Fanconi anemia complementation group D2 (Fancd2) knockout mice. Genes Dev 17: 2021–2035.
Howlett NG, Taniguchi T, Olson S, Cox B, Waisfisz Q, De Die-Smulders C et al. (2002). Biallelic inactivation of BRCA2 in Fanconi anemia. Science 297: 606–609.
Hu N, Li G, Li WJ, Wang C, Goldstein AM, Tang ZZ et al. (2002). Infrequent mutation in the BRCA2 gene in esophageal squamous cell carcinoma. Clin Cancer Res 8: 1121–1126.
Hu N, Li WJ, Su H, Wang C, Goldstein AM, Albert PS et al. (2003). Common genetic variants of TP53 and BRCA2 in esophageal cancer patients and healthy individuals from low and high risk areas of northern China. Cancer Detect Prev 27: 132–138.
Hu N, Roth MJ, Polymeropolous M, Tang ZZ, Emmert-Buck MR, Wang QH et al. (2000). Identification of novel regions of allelic loss from a genomewide scan of esophageal squamous cell carcinoma in a high-risk Chinese population. Genes Chromosomes Cancer 27: 217–228.
Hu N, Wang C, Han XY, He LJ, Tang ZZ, Giffen C et al. (2004). Evaluation of BRCA2 in the genetic susceptibility of familial esophageal cancer. Oncogene 23: 852–858.
Hughes-Davies L, Huntsman D, Ruas M, Fuks F, Bye J, Chin SF et al. (2003). EMSY links the BRCA2 pathway to sporadic breast and ovarian cancer. Cell 115: 523–535.
Hussain S, Witt E, Huber PA, Medhurst AL, Ashworth A, Mathew CG . (2003). Direct interaction of the Fanconi anaemia protein FANCG with BRCA2/FANCD1. Hum Mol Genet 12: 2503–2510.
International HapMap Consortium (2005). A haplotype map of the human genome. Nature 437: 1299–1320.
Islami F, Kamangar F, Aghcheli K, Fahimi S, Semnani S, Taghavi N et al. (2004). Epidemiologic features of upper gastrointestinal tract cancers in Northeastern Iran. Br J Cancer 90: 1402–1406.
Joenje H, Patel KJ . (2001). The emerging genetic and molecular basis of Fanconi anaemia. Nat Rev Genet 2: 446–457.
Li G, Hu N, Goldstein AM, Tang ZZ, Roth MJ, Wang QH et al. (2001). Allelic loss on chromosome bands 13q11-q13 in esophageal squamous cell carcinoma. Genes Chromosomes Cancer 31: 390–397.
Lowenfels AB, Maisonneuve P . (2005). Risk factors for pancreatic cancer. J Cell Biochem 95: 649–656.
Mahboubi E, Kmet J, Cook PJ, Day NE, Ghadirian P, Salmasizadeh S . (1973). Oesophageal cancer studies in the Caspian littoral of Iran: the Caspian cancer registry. Br J Cancer 28: 197–214.
Marmorstein LY, Kinev AV, Chan GK, Bochar DA, Beniya H, Epstein JA et al. (2001). A human BRCA2 complex containing a structural DNA binding component influences cell cycle progression. Cell 104: 247–257.
Martin ST, Matsubayashi H, Rogers CD, Philips J, Couch FJ, Brune K et al. (2005). Increased prevalence of the BRCA2 polymorphic stop codon K3326X among individuals with familial pancreatic cancer. Oncogene 24: 3652–3656.
Mazoyer S, Dunning AM, Serova O, Dearden J, Puget N, Healey CS et al. (1996). A polymorphic stop codon in BRCA2. Nat Genet 14: 253–254.
McAllister KA, Bennett LM, Houle CD, Ward T, Malphurs J, Collins NK et al. (2002). Cancer susceptibility of mice with a homozygous deletion in the COOH-terminal domain of the Brca2 gene. Cancer Res 62: 990–994.
Milner J, Ponder B, Hughes-Davies L, Seltmann M, Kouzarides T . (1997). Transcriptional activation functions in BRCA2. Nature 386: 772–773.
Mizuta R, LaSalle JM, Cheng HL, Shinohara A, Ogawa H, Copeland N et al. (1997). RAB22 and RAB163/mouse BRCA2: proteins that specifically interact with the RAD51 protein. Proc Natl Acad Sci USA 94: 6927–6932.
Morimatsu M, Donoho G, Hasty P . (1998). Cells deleted for Brca2 COOH terminus exhibit hypersensitivity to gamma-radiation and premature senescence. Cancer Res 58: 3441–3447.
Narod SA . (2002). Modifiers of risk of hereditary breast and ovarian cancer. Nat Rev Cancer 2: 1372–1375.
Offit K, Levran O, Mullaney B, Mah K, Nafa K, Batish SD et al. (2003). Shared genetic susceptibility to breast cancer, brain tumors, and Fanconi anemia. J Natl Cancer Inst 95: 1548–1551.
Pellegrini L, Yu DS, Lo T, Anand S, Lee M, Blundell TL et al. (2002). Insights into DNA recombination from the structure of a RAD51-BRCA2 complex. Nature 420: 287–293.
Pour P, Ghadirian P . (1974). Familial cancer of the esophagus in Iran. Cancer 33: 1649–1652.
Reid S, Schindler D, Hanenberg H, Barker K, Hanks S, Kalb R et al. (2007). Biallelic mutations in PALB2 cause Fanconi anemia subtype FA-N and predispose to childhood cancer. Nat Genet 39: 162–164.
Rosenberg PS, Greene MH, Alter BP . (2003). Cancer incidence in persons with Fanconi anemia. Blood 101: 822–826.
Saidi F, Sepehr A, Fahimi S, Farahvash MJ, Salehian P, Esmailzadeh A et al. (2000). Oesophageal cancer among the Turkomans of northeast Iran. Br J Cancer 83: 1249–1254.
Schottenfeld D . (1984). Epidemiology of cancer of the esophagus. Semin Oncol 11: 92–100.
Simard J, Dumont M, Labuda D, Sinnett D, Meloche C, El-Alfy M et al. (2003). Prostate cancer susceptibility genes: lessons learned and challenges posed. Endocr Relat Cancer 10: 225–259.
Sunyaev S, Ramensky V, Koch I, Lathe W, Kondrashov AS, Bork P . (2001). Prediction of deleterious human alleles. Hum Mol Genet 10: 591–597.
Taniguchi T, D'Andrea AD . (2006). Molecular pathogenesis of Fanconi anemia: recent progress. Blood 107: 4223–4233.
Tian XX, Rai D, Li J, Zou C, Bai Y, Wazer D et al. (2005). BRCA2 suppresses cell proliferation via stabilizing MAGE-D1. Cancer Res 65: 4747–4753.
Wang X, Andreassen PR, D'Andrea AD . (2004). Functional interaction of monoubiquitinated FANCD2 and BRCA2/FANCD1 in chromatin. Mol Cell Biol 24: 5850–5862.
Wooster R, Bignell G, Lancaster J, Swift S, Seal S, Mangion J et al. (1995). Identification of the breast cancer susceptibility gene BRCA2. Nature 378: 789–792.
Xia B, Sheng Q, Nakanishi K, Ohashi A, Wu J, Christ N et al. (2006). Control of BRCA2 cellular and clinical functions by a nuclear partner, PALB2. Mol Cell 22: 719–729.
Yang H, Jeffrey PD, Miller J, Kinnucan E, Sun Y, Thoma NH et al. (2002). BRCA2 function in DNA binding and recombination from a BRCA2-DSS1-ssDNA structure. Science 297: 1837–1848.
Acknowledgements
We thank Dr Haj-amin Marjani, Dr Noushin Taghavi and Dr Fatemeh Rajabzadeh from the case–control study center (Atrak Clinic) in Gonbad city for helping with study subject recruitment. We also appreciate the kind help of Ofelia Francisco-Pabalan, Cheryl Crozier and Swan Cot for laboratory testings. This study was supported by grants from the Canadian Institutes of Health Research (CIHR) and the Digestive Disease Research Center (DDRC), Tehran University of Medical Sciences (TUMS).
Author information
Authors and Affiliations
Corresponding authors
Rights and permissions
About this article
Cite this article
Akbari, M., Malekzadeh, R., Nasrollahzadeh, D. et al. Germline BRCA2 mutations and the risk of esophageal squamous cell carcinoma. Oncogene 27, 1290–1296 (2008). https://doi.org/10.1038/sj.onc.1210739
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.onc.1210739
Keywords
This article is cited by
-
Integrated cohort of esophageal squamous cell cancer reveals genomic features underlying clinical characteristics
Nature Communications (2022)
-
Reversion mutations in germline BRCA1/2-mutant tumors reveal a BRCA-mediated phenotype in non-canonical histologies
Nature Communications (2022)
-
Germline Cancer Testing in Unselected Patients with Gastric and Esophageal Cancers: A Multi-center Prospective Study
Digestive Diseases and Sciences (2022)
-
Phase I and pharmacokinetic study of veliparib, a PARP inhibitor, and pegylated liposomal doxorubicin (PLD) in recurrent gynecologic cancer and triple negative breast cancer with long-term follow-up
Cancer Chemotherapy and Pharmacology (2020)
-
Genetic and molecular bases of esophageal Cancer among Iranians: an update
Diagnostic Pathology (2019)